We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 3

2.
Figure 3

Figure 3. From: Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.

Virological responses in treatment-naïve patients and in those who were previously treated with interferon-based therapy.

Hamad Al Ashgar, et al. Ann Saudi Med. 2009 Jan-Feb;29(1):4-14.
3.
Figure 1

Figure 1. From: Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.

Serum alanine aminotransferase (mean, standard deviation) in patients with sustained virological response (n=66) and in those who relapsed after end-of-treatment response (n=30) at baseline, 24, 48, and 72 weeks ost-treatment. aP=.001 vs. viral relapses.

Hamad Al Ashgar, et al. Ann Saudi Med. 2009 Jan-Feb;29(1):4-14.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk